March 25, 2020 / 11:40 AM / 12 days ago

BRIEF-Silence Therapeutics Says Board Has Taken Decision To Accelerate SLN360

March 25 (Reuters) - Silence Therapeutics PLC:

* SILENCE THERAPEUTICS ANNOUNCES RESEARCH AND DEVELOPMENT UPDATE

* SILENCE THERAPEUTICS PLC - BOARD HAS TAKEN DECISION TO ACCELERATE SLN360

* SILENCE THERAPEUTICS PLC - INTENDS TO SUBMIT INVESTIGATIONAL NEW DRUG APPLICATION WITH U.S. FDA LATER IN 2020

* SILENCE THERAPEUTICS PLC - FOR SLN124, HAVE DECIDED TO PAUSE PATIENT RECRUITMENT UNDER CURRENT PROTOCOL

* SILENCE THERAPEUTICS PLC - HAS BEEN NOTIFIED BY FDA THAT SLN124 HAS BEEN GRANTED RARE PEDIATRIC DISEASE DESIGNATION FOR TREATMENT OF Β THALASSEMIA Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below